Histone Deacetylase Inhibitors
Section: For Industry
Category(ies): Cancer Therapeutics
Reference #: BRMI430501
OTC Contact: Dave Odelson, Ph.D. (Directory Information | Send a Message)
Description
Histone Deacetylase (HDAC) inhibitors can sensitize cancers to chemotherapy and radiation therapy. There are some HDAC inhibitors that are currently being tested in clinical trials but there exists a need for new and more effective HDAC inhibitors which are optimal with respect to efficacy, toxicity, and isoform-specificity. The present invention describes fluorescently labeled novel HDAC inhibitors that exert effects at lower concentrations with varying effectiveness against HDAC isoforms.
Applications
- Fluorescently labeled hence inhibitor can be visualized
- Effective at lower concentrations.
- Act by a novel mechanism
Advantages
Stage of Development
Stage of Development: Proof of concept demonstrated in cell lines.
Relevant Publications
No references or resources available.
Patent Status
Patent application filed.
